論文・技術情報追加のお知らせ

1. Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system.

オシメルチニブ、筋毒性リスクを解析し安全性評価

対象DB：FAERS

2. A pharmacovigilance study of the association between linaclotide/plecanatide and muscle spasms based on food and drug administration adverse event reporting system.

リンアクロチド/プレカナチド、筋痙攣発生と初期リスク解析

対象DB：FAERS

3. Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database.

TMZ、血液毒性と新規AEを確認し安全性を検証

対象DB：FAERS

4. Real-world drug safety study of somatostatin analogs based on the Food and Drug Administration Adverse Event Reporting System database.

SSAs、既知及び新規AEを確認し安全性を評価

対象DB：FAERS

5. A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab.

エミシズマブ、早期AE監視と併用薬リスクに注目

対象DB：FAERS

6. Mining and evaluation of security alert signals of neuroprotective agents based on the Jinan adverse event reporting system database: a retrospective study.

神経保護薬、Jinanデータで警告と未記載AEを確認

対象DB：FAERS

7. Post-Marketing Safety Profile of Ertugliflozin: Insights from a Real-World Pharmacovigilance Analysis based on the FAERS database.

エルトグリフロジン、安全性シグナルと早期AEリスクを評価

対象DB：FAERS

8. Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006-december 2024).

RZV vs ZVL：安全性評価とGBS要検討

対象DB：FAERS,VAERS

9. Updating understanding of real-world adverse events associated with omeprazole.

オメプラゾール、新規AEと腎障害リスクを再評価

対象DB：FAERS

10. Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system.

偏頭痛薬、特定のトリプタンとCGRP阻害薬で耳鳴り

対象DB：FAERS,KAERS

11. A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat.

タゼメトスタット、新規AEと既知毒性をFAERS解析で確認

対象DB：FAERS

12. Pharmacovigilance analysis of metabolic and nutritional adverse reactions associated with entecavir and tenofovir using the FDA adverse event reporting system database.

エンテカビルとテノホビル、新規代謝栄養ADRリスク確認

対象DB：FAERS

13. Signal mining and risk analysis of tisotumab vedotin adverse events based on the FAERS database.

ティソツマブ・ベドチン、眼疾患と新AEに注意必要

対象DB：FAERS

14. Adverse Event Profile Differences Between Metyrapone and Osilodrostat: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.

オシロドロスタットとメチラポン、AE解析で新リスク発見

対象DB：FAERS

15. Pembrolizumab-associated hepatobiliary disorders: a real-world pharmacovigilance study using the FDA Adverse Events Reporting System (FAERS).

ペンブロリズマブ、肝胆道障害AEのリスク解析結果

対象DB：FAERS

16. Meningioma in users of progestogen contraceptives: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).

プロゲストーゲン避妊薬、髄膜腫リスク一部確認

対象DB：FAERS

17. Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system.

抗うつ薬の神経有害事象、薬剤・年齢で多様なリスク確認

対象DB：FAERS

18. Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study.

RRMM治療TCEsの神経有害事象、TLがリスク上昇示唆

対象DB：FAERS

19. Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell-Derived Cardiomyocytes and FDA Adverse Events Reporting System.

iPSC-CM解析、オシメルチニブ心筋収縮障害リスク予測

対象DB：FAERS

20. Age and Sex Differences in Adverse Events Associated With Antipsychotics: An Analysis of the FDA Adverse Events Database.

抗精神病薬の副作用、年齢・性差で異なるリスク確認

対象DB：FAERS

21. Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis.

薬剤誘発性記憶障害の関連詳細提示

対象DB：FAERS

22. Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance database.

オランザピンなど薬物、行動依存リスクに関連示唆

対象DB：VigiBase

23. Analysis of hemorrhagic transformation and intracerebral hemorrhage under combination therapy with alteplase and antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database.

アルテプラーゼ併用療法、HTとICHリスク注意喚起

対象DB：JADER

24. Effect of oral proton pump inhibitor administration on reducing the delayed bleeding risk in five upper gastrointestinal endoscopic treatments.

PPI服用、胃内視鏡治療後の遅延出血リスク低減

対象DB：DPC

25. Effectiveness of the presence of diabetologists for perioperative complications in patients with diabetes undergoing colorectal cancer surgery: A nationwide inpatient database in Japan.

糖尿病専門医の存在、周術期合併症リスク軽減示唆

対象DB：DPC

26. External Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Diseases in a Large National Health-Checkup and Claim Database.

久山モデル、ASCVD予測で全国健診の有用性確認

対象DB：NDB

27. Between-practice variation in chronic obstructive pulmonary disease diagnosis guideline compliance: database study.

COPD診断支援、肺機能検査とX線利用向上必要

対象DB：CPRD

28. Longitudinal trajectories of polypharmacy in older people, and their association with the risk of mortality: a joint latent class model analysis of real-world data from the UK and the Netherlands.

高齢者の多剤併用歴、死亡リスクと関連性確認

対象DB：CPRD

29. Increased 30-day mortality associated with weekend emergency admission for alcohol-related liver disease in England: a record-linkage study using the Clinical Practice Research Datalink.

ARLD週末入院、30日死亡率12-19%増加示唆

対象DB：CPRD

30. rcprd: An R package to simplify the extraction and processing of Clinical Practice Research Datalink (CPRD) data, and create analysis-ready datasets.

CPRDデータ効率化ツールで研究作業を簡略化

対象DB：CPRD

31. Identifying Treatable Traits of Patients with Asthma Prescribed an ICS/LABA: A Descriptive Analytic Database Study in England.

喘息増悪とSABA使用、個別化治療の重要性示唆

対象DB：CPRD

32. Co-prescribing of antidepressants and opioids for non-cancer pain in England, 2010-2019: a descriptive study using CPRD primary care electronic health records.

英国におけるオピオイドと抗うつ薬併用、リスク評価必要

対象DB：CPRD

33. Mortality Outcomes and ACE Inhibitor Use in Patients with Idiopathic Pulmonary Fibrosis.

ACE阻害薬、IPF患者の死亡率低下との関連確認

対象DB：CPRD

34. Trends in mortality in people with heart failure and atrial fibrillation: a population-based cohort study.

心不全と心房細動併存、予後悪化と社会的格差確認

対象DB：CPRD

35. Ketoacidosis associated with type 2 sodium-glucose cotransporter inhibitors (SGLT2i) in patients aged 65 and older: Evidence from the French national pharmacovigilance database.

高齢者SGLT2阻害薬使用、DKAリスク管理の重要性

対象DB：FPVD

36. NSAID-Induced acute kidney injury risk in patients on renin-angiotensin system inhibitors and diuretics: nationwide cohort study.

NSAIDs併用と腎障害リスク、安全管理の重要性強調

対象DB：DeSC